CMPI.org

In the News

FDA Hears Concerns About The Unregulated CBD Market

06/04/2019 12:00 AM | Forbes

Restoring the Balance Between Innovation and Generic Manufacturing of Medicines

04/26/2019 12:00 AM | CMPI

How ‘Right to Try’ Laws Fail Patients Who Need Experimental Medicine

04/24/2019 12:00 AM | Observer

Doggett-Brown Bill Destroys Drug Innovation

04/23/2019 12:00 AM | Inside Sources

A front for government price controls

04/22/2019 12:00 AM | The Washington Times

Peter Pitts discusses New York lawsuit against Opioid manufacturer on i24NEWS

04/01/2019 12:00 AM | i24NEWS

Health Care Chutzpah vs. Health Plan Literacy

03/14/2019 12:00 AM |

Peter Pitts moderates CPAC Panel - Promises Made, Promises Unkept: Time to get Serious About Healthcare

03/04/2019 12:00 AM |

America's health at stake

02/26/2019 12:00 AM | The Washington Times

Understanding the FDA's Take on Cannabidiol

02/19/2019 12:00 AM | Cancer Therapy Advisor

It’s time to get serious about the economics of expanded access

01/30/2019 12:00 AM | STAT

Health sharing, a viable option for health care

01/08/2019 12:00 AM | The Washington Times

Elizabeth Warren's Threat to Medical Progress

01/06/2019 12:00 AM | RealClearHealth

HHS Drug Price Plan Is a Gift to Global ‘Freeloaders’

12/27/2018 12:00 AM | RealClearHealth

Zeroing Out Drug Prices

12/17/2018 12:00 AM | Morning Consult

Keeping the government out of Medicare Part D

12/04/2018 12:00 AM | The Washington Times

FDA and Juul E-Cig Regs Should Keep Anti-Smoking Zealots at Bay

11/16/2018 12:00 AM | RealClearHealth

Streamline drug approval process

11/11/2018 12:00 AM | Echo Press

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

11/06/2018 12:00 AM | The Washington Times

Medicines regulation in the MENA region and the importance of the World Health Organization’s INN proposal of Biological Qualifier

11/02/2018 12:00 AM | Generics and Biosimilars Initiative Journal

Previous
1
2
3
4
5
6
7
...
9
Next

RECENT NEWS

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

FDLI
09/07/2021 12:00 AM

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta... Read more

FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15

NEWSY
01/04/2022 12:00 AM

FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15

CMPI's Peter Pitts discusses FDA approval of Pfizer COVID vaccine booster for children ages 12-15... Read more

Should We Rethink The FDA Commissionership?

Health Affairs
12/22/2021 12:00 AM

Should We Rethink The FDA Commissionership?

When one considers the FDA’s mission—to independently protect consumers and advance the public health—it is not at all cl... Read more

Read all News